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Abstract
 
Tyrosine kinase receptors for angiogenic factors vascular endothelial growth factor (VEGF) and
angiopoietin-1 (Ang-1) are expressed not only by endothelial cells but also by subsets of he-
matopoietic stem cells (HSCs). To further define their role in the regulation of postnatal he-
matopoiesis and vasculogenesis, VEGF and Ang-1 plasma levels were elevated by injecting re-
 
combinant protein or adenoviral vectors expressing soluble VEGF
 
165
 
, matrix-bound VEGF
 
189
 
,
or Ang-1 into mice. VEGF
 
165
 
, but not VEGF
 
189
 
, induced a rapid mobilization of HSCs and
 
VEGF receptor (VEGFR)2
 
1
 
 circulating endothelial precursor cells (CEPs). In contrast, Ang-1
induced delayed mobilization of CEPs and HSCs. Combined sustained elevation of Ang-1 and
VEGF
 
165 
 
was associated with an induction of hematopoiesis and increased marrow cellularity
followed by proliferation of capillaries and expansion of sinusoidal space. Concomitant to this
vascular remodeling, there was a transient depletion of hematopoietic activity in the marrow,
which was compensated by an increase in mobilization and recruitment of HSCs and CEPs to
the spleen resulting in splenomegaly. Neutralizing monoclonal antibody to VEGFR2 com-
pletely inhibited VEGF
 
165
 
, but not Ang-1–induced mobilization and splenomegaly. These data
suggest that temporal and regional activation of VEGF/VEGFR2 and Ang-1/Tie-2 signaling
pathways are critical for mobilization and recruitment of HSCs and CEPs and may play a role
in the physiology of postnatal angiogenesis and hematopoiesis.
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Introduction
 
In the adult, the majority of hematopoietic stem cells
 
(HSCs)
 
1
 
 (1) and circulating endothelial precursor cells
(CEPs; references 2–4) reside in the bone marrow (BM).
However, upon stimulation with various cytokines, HSCs
and CEPs can be mobilized to the peripheral circulation and
colonize other hematopoietic organs, such as the spleen. In
addition, BM failure states secondary to BM fibrosis (my-
elofibrosis) or certain metastatic neoplastic diseases are asso-
ciated with relocalization of HSCs from BM to extramed-
ullary hematopoietic macroenvironments, including the
spleen resulting in splenomegaly (5). However, the exact
identities of the chemocytokines responsible for the mobili-
zation and the mechanism of extramedullary recruitment of
BM-derived HSCs and CEPs are not well established.
Given the common prenatal origin of CEPs and HSCs
from hemangioblasts, both hematopoietic and vasculogenic
cells share several survival and chemotactic signaling path-
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ways. The tyrosine kinase receptors, VEGFR2 (Flk-1,
KDR; reference 6) and Tie-2 (7), whose expression was
originally shown to be restricted to vascular cells, are also
shared by subsets of HSCs. Angiopoietin-1 (Ang-1), the
natural ligand for Tie-2 (8), in conjunction with VEGF,
modulates various aspects of angiogenesis such as remodel-
ing (9–12) and vascular permeability (13). Furthermore,
Ang-1 and VEGF exert a synergistic effect in promoting
the survival of hematopoietic progenitor cells in the devel-
oping aorta-gonad-mesonephros (14, 15). In addition to
conveying signals that regulate cell proliferation, VEGF and
Ang-1 also promote chemotaxis and chemokinesis of en-
dothelial cells (11, 12). Since VEGF plasma levels are ele-
vated in the circulation during tumor growth (16) and BM
failure states (17), we hypothesized that angiogenic factors
may play a role in the pathogenesis of postnatal hematopoi-
etic dysfunction and splenomegaly. In this regard, we spec-
ulated that acute or chronic regional overexpression of an-
giogenic factors, such as VEGF and Ang-1, may regulate
hematopoiesis by promoting the extramedullary mobiliza-
tion and recruitment of HSCs and CEPs.
Adenoviral (Ad) vectors are ideal vectors for the high
level expression of angiogenic factors with chemokinetic
potential because they allow for regional expression of a
given chemokine for durations long enough to exert their
physiological effect. The intravenous injection of Ad vec-
tors into SCID mice results primarily in the localization of
the Ad vectors to the extramedullary organs, including liver
and, to a smaller degree, spleen. Therefore, to mimic phys-
iological conditions of sustained plasma release of VEGF
and Ang-1, we delivered Ad vectors expressing Ang-1 and
isoforms of VEGF (including soluble VEGF
 
165
 
 and matrix-
bound VEGF
 
189
 
) to extramedullary organs of immunocom-
promised SCID mice. In this regard, Ad vectors are ideal
vectors for the expression of factors with chemokinetic po-
tential because they allow for regional expression at high ti-
ters long enough to exert their physiological effect.
We demonstrate that plasma elevation of VEGF and/or
Ang-1 results in the mobilization of HSCs and CEPs.
Combined elevation of VEGF and Ang-1 resulted in re-
modeling of the BM vasculature with concomitant sple-
nomegaly. These studies suggest that temporal and regional
activation of VEGF/VEGFR2 and Ang-1/Tie-2 signaling
pathways are critical for mobilization and recruitment of
HSCs and CEPs and may play a role in the pathogenesis of
hematopoietic dysfunction and physiology of postnatal an-
giogenesis and hematopoiesis.
 
Materials and Methods
 
Animals.
 
Immunodeficient age- (8 wk), weight- (
 
.
 
20 g),
and sex-matched SCID mice (on BALB/c background) were
purchased from the The Jackson Laboratory and maintained in
filtered air Thorensen units. All mice received the Ad vector ex-
pressing VEGF
 
165 
 
(AdVEGF
 
165
 
; 1.5 
 
3 
 
10
 
8
 
 PFU) and/or the
AdAng-1 (10
 
9
 
 PFU), the AdNull vector (no transgene; 10
 
9
 
 PFU),
or the AdVEGF
 
189
 
 vector (2 
 
3
 
 10
 
8
 
 PFU) in a volume of 100 
 
m
 
l,
by single intravenous administration on day 0. Each study in-
 
volved three to four animals. Age-matched female BALB/c and
C57BL/6 mice were used in CFU-S assay/allogeneic peripheral
blood cell transplantation as recipients.
 
Ad Vectors.
 
AdVEGF
 
165 
 
and AdVEGF
 
189
 
 are Ad5-derived
E1a-, E3-deficient (E1a-E3-E4
 
1
 
) vectors with an expression cas-
sette in the E1a region containing the murine VEGF
 
165 
 
cDNA/
human VEGF
 
189
 
 cDNA driven by the CMV major immediate/
early promoter/enhancer. The control vector, AdNull, is similar
in design except that it contains no transgene in the expression
cassette. AdAng-1 is constructed using the Adeno-Quest™ sys-
tem from Quantum Biotechnology, Inc. Full-length cDNAs en-
coding an engineered version of human Ang-1 called Ang-1
 
*
 
were cloned into shuttle vector pQBI-AdCMV5 green fluores-
cent protein. Linearized plasmid and viral long-arm DNA were
cotransfected into 293 cells as described previously (18).
 
Immunoassays of Cytokines.
 
Murine VEGF plasma levels were
evaluated using commercial ELISA (R&D Systems) following the
manufacturer’s instructions. Human plasma Ang-1 levels were
also measured using a sensitive ELISA (Regeneron).
 
Peripheral Blood Analysis.
 
Initially every 2–3 d and later on a
weekly basis, retroorbital blood was collected with capillary pi-
pettes (Unopette; Fisher Scientific). Platelets, total white blood
cells (WBCs), and granulocytes (polymorphonuclear leukocytes)
were counted using a Neubauer hematocytometer (Fisher Scien-
tific). Differential leukocyte counts were obtained by examina-
tion of blood smears from each mouse stained with Wright-
Giemsa stain (200 cells counted/smear). The plasma samples were
collected, stored at 
 
2
 
80
 
8
 
C, and assessed later by immunoassay for
murine VEGF and human Ang-1.
 
Flow Cytometry.
 
A total of 10
 
4
 
 to 10
 
5
 
 cells were incubated for
30 min at 4
 
8
 
C with the following FITC- or PE-conjugated mAbs:
H-2K
 
b
 
–FITC (AF6-88.5; BD PharMingen); CD11b-FITC (M1/
70; BD PharMingen); and H-2K
 
d
 
–FITC (SF-1-1.1; BD PharMin-
gen). DC101 (VEGFR2)–FITC (ImClone Systems) was devel-
oped and characterized as described previously (19). Propidium io-
dide (Becton Dickinson) was dissolved at 3 mM in PBS and used
at 30 
 
m
 
M. The cells were analyzed by two-color flow cytometry
using an Coulter Elite flow cytometer (Beckman Coulter).
 
Spleen and BM Analysis.
 
BM was obtained by flushing both
femoral bones with 3 ml of cold (4
 
8
 
C) IMDM containing 20%
FCS. Manual leukocyte differentials were performed on Wright-
Giemsa–stained cytospin preparations of BM cells and splenocytes.
The number of megakaryocytes in randomly chosen femoral BM
and spleen samples was determined using 400
 
3 
 
magnification
field light microscopy.
 
Progenitor Assay.
 
PBMCs were collected from orbital plexus
and isolated after centrifugation over a discontinuous gradient us-
ing lympholyte-M. PBMCs (10
 
5
 
 cells) were plated in triplicate in
1 ml of 0.8% methylcellulose containing 30% FCS, 1% 
 
L
 
-glu-
tamine, 2.5% hemin, 0.05 mM 5-ME, IL-3 (50 ng/ml; R&D
Systems), c-kit ligand (20 ng/ml; Immunex), and erythropoietin
(2 U/ml; Sandoz) in 35-mm suspension culture dishes. Scoring
was performed with an inverted microscope (40
 
3
 
) on day 7.
Cells from PBMCs obtained from AdVEGF
 
165
 
- and/or AdAng-
1–treated mice were seeded in the colony assays and four CFU
types were scored: CFU-GM, BFU-E, CFU-M, and CFU-Mix,
3, 5, 14, 28 d after the onset of treatment. CEPs present in the
mobilized PBMCs were quantified as described previously (4,
20). Freshly isolated PBMCs obtained from mice treated with
AdVEGF and/or AdAng-1 on days 3 and 14 were cultured in
endothelial growth medium (M199; GIBCO BRL) supple-
mented with 20% fetal bovine serum (HyClone), endothelial cell
growth factor (30 
 
m
 
g/ml), fibroblast growth factor (FGF) (5 ng/ 
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ml, human recombinant basic FGF; Sigma-Aldrich), heparin (5
U/ml), penicillin (100 U/mL), streptomycin (100 
 
m
 
g/ml), and
fungizone (0.25 
 
m
 
g/ml). These cells were placed on 12-well gel-
atin-coated plates. After 2–3 wk, the endothelial colonies were
identified by metabolic uptake of DiI-acetylated-LDL (DiI-Ac-
LDL; PerImmune, Inc.) by incubating the wells with 1 
 
m
 
g/ml of
human DiI-Ac-LDL for 5 h and visualized by fluorescence mi-
croscopy. For von Willebrand factor (vWF) staining, cells were
rinsed with HBSS and fixed immediately with ethanol for 10
min. DiI-Ac-LDL
 
1
 
vWF
 
1
 
 colonies formed in the first 3 d after
vector administration were scored as early outgrowth endothelial
colonies, whereas endothelial colonies formed after 14 d of cul-
ture were considered as late-outgrowth colonies (CFU-ECs).
 
CFU-S Assay.
 
Mobilized PBMCs were obtained from days
3, 5, 7, 14, 21, and 28 after the onset of treatment with various
Ad vectors. For each data point, three recipient mice were irradi-
ated with 9 Gy from a 
 
137
 
Cs 
 
g
 
-ray source at a dose rate of 
 
z
 
0.90
Gy/min to prevent the production of endogenous spleen colo-
nies. Irradiated mice were injected intravenously via the tail vein
with 10
 
5
 
 PBMCs within several hours after the completion of ir-
radiation. The mice were killed 12 d later, and their spleens were
removed and fixed in Bouin’s solution. The number of macro-
scopic spleen colonies was then scored.
 
Repopulating Assay.
 
After vector administration, the periph-
eral blood from SCID mice was collected on day 7. PBMCs (10
 
6
 
cells) were transplanted into lethally irradiated (9.5 Gy) recipient
C57BL/6 mice. As a control, PBMCs (10
 
6
 
 cells) from AdNull-
treated SCID mice were transplanted into irradiated C57BL/6
mice by intravenous injection at day 0. Chimerism was deter-
mined by FACS
 
®
 
 analysis (donor SCID mice, H-2K
 
d
 
; recipient
C57BL/6 mice, H-2K
 
b
 
). The chimeric mice were killed at 90,
120, and 150 d after transplantation and BM mononuclear cells
(BMMCs) were stained for flow cytometry analysis with H-2K
 
d
 
–
FITC (donor type). The representative percentages of positive
populations in BMMCs are shown at day 150 (see Fig. 2 C). The
data from age-matched normal C57BL/6 mice are also repre-
sented as control. A total of 10
 
4
 
 cells were incubated for 30 min
at 4
 
8
 
C with FITC- or PE-conjugated mAbs, H-2K
 
b
 
–FITC (AF6-
88.5; BD PharMingen) and H-2K
 
d
 
–FITC (SF-1-1.1; BD
PharMingen). The percentage of positive cells was analyzed
by flow cytometry using an Elite flow cytometer (Beckman
Coulter). Survival was monitored every day until 150 d after vec-
tor administration. As control, BMMCs (10
 
6
 
) from SCID mice
were transplanted into irradiated C57BL/6 mice by intravenous
injection at day 0.
 
Histopathology.
 
Tissues were fixed in 10% buffered formalin
and paraffin embedded. Sections were stained with hematoxylin
and eosin and examined under microscopy.
 
Delivery of Neutralizing VEGFR2 mAb to Mice.
 
A group of
SCID mice were treated with 1.5 
 
3
 
 10
 
8 
 
PFU of AdVEGF
 
165
 
, 1.5 
 
3
 
10
 
8 
 
PFU of AdVEGF
 
165
 
 and 10
 
9 
 
PFU of AdAng-1, or 10
 
9 
 
PFU of
AdNull intravenously on day 0. Some AdVEGF
 
165
 
-, AdVEGF
 
165
 
-
and AdAng-1–, or AdNull-treated SCID mice received 800
 
 m
 
g
of anti-VEGFR2 (clone DC101) mAb intraperitoneally at 2-d in-
tervals from either day 0 or 2.
 
Recombinant VEGF Induces Splenomegaly in Mice.
 
A group of
BALB/c mice were treated with 100 ng/mice recombinant
VEGF or PBS intraperitoneally daily. Recombinant VEGF was
purchased from Immunotech.
 
Statistical Evaluation.
 
The results are expressed as mean 
 
6
 
SEM. Statistical analyses were performed using the unpaired two-
tailed Student’s 
 
t
 
 test. Survival rates were compared between the
two groups by the log rank test.
 
Results
 
AdAng-1 and AdVEGF
 
165
 
 but Not AdVEGF
 
189 
 
Promote
Mobilization of Hematopoietic Cell
 
s. Intravenous administra-
tion of Ad vectors expressing VEGF
 
165
 
 (AdVEGF
 
165
 
, 1.5 
 
3
 
10
 
8
 
 PFU) resulted in a peak VEGF plasma level (1,640 
 
6
 
233 pg/ml) 24 h after injection and a return to pretreatment
level on day 35. Doses .1.5 3 108 PFU of AdVEGF165
were significantly toxic and resulted in the death of the
treated mice (data not shown). There were no signs of tox-
icity in mice treated with AdNull vectors at doses up to 109
PFU. In AdAng-1–treated mice (109 PFU), plasma levels of
Ang-1 peaked on day 3 after injection (74.1 6 0.7 ng/ml),
returning to the pretreatment level after 8 wk. Plasma VEGF
and Ang-1 were not detectable in AdNull-treated mice.
To examine the effects of acute and chronic elevation of
circulating VEGF165 or Ang-1 levels in the mobilization of
CEPs and HSCs, SCID mice were injected intravenously
with AdVEGF165 (1.5 3 108 PFU) and/or AdAng-1 (109
PFU), or AdVEGF189 (2 3 108 PFU). Subsequently, the
number of leukocytes, hematopoietic progenitor cells, and
HSCs were determined in the peripheral blood. Control
mice were injected with 109 PFU of AdNull vector. Com-
pared with AdNull-treated mice, AdVEGF165-treated mice
had a fourfold increase in WBCs on day 3, returning to the
level of AdNull-treated mice by 5 wk after injection (Fig. 1
A). In contrast, administration of AdAng-1 into SCID mice
resulted in only a small increase in WBCs, peaking at day
17 and returning to control levels by 7 wk. However, the
combination of AdVEGF165 and AdAng-1 resulted in a
synergistic sevenfold increase in WBCs 5 d after vector ad-
ministration. As expected, injection of AdVEGF189, which
results in production of matrix-bound VEGF189, did not
result in leukocyte mobilization.
Populations of blast-like cells that are usually localized to
the BM were detected at high levels in the peripheral circu-
lation of the AdVEGF165- and/or AdAng-1–treated mice.
These cells displayed scant cytoplasm and large nuclei, remi-
niscent of BM-derived immature hematopoietic progenitor
and precursor cells (Fig. 1 B). Compared with AdNull-
treated mice, AdVEGF165- and AdVEGF165 plus AdAng-1–
treated mice had a dramatic increase in the WBC percentage
of blast-like cells (Others; Fig. 1 B) and monocytes during
days 2–14, returning almost to baseline 3 wk after the start of
treatment (Fig. 1 C). The intravenous administration of
AdAng-1 to SCID mice also resulted in increased circulation
of blast-like cells, peaking at day 16 and returning to baseline
on day 49 (Fig. 1 C). There were no significant changes in
the leukocyte levels of AdNull-treated mice.
AdVEGF165 and AdAng-1 Induced Mobilization of Hemato-
poietic Progenitor Cells with Stem Cell Potential. The admin-
istration of AdVEGF165 induced mobilization of hemato-
poietic progenitors to the peripheral circulation. These
progenitors comprised colony-forming units (CFU-Cs)
such as CFU-M, CFU-GM, BFU-E, and CFU-Mix
(CFU-GEMM). Compared with AdNull-treated mice, at
days 3 and 5 the majority of the mobilized CFU-Cs con-
sisted of CFU-GM (*P , 0.005). CFU-GMs peaked at day1008 VEGF and Ang-1 Stimulate Postnatal Hematopoiesis
5 and returned to baseline levels by day 28 (Fig. 2 A). The
remaining leukocytes mobilized to the peripheral blood
consisted of mature cells including monocytes.
Administration of AdAng-1 promoted a delayed but sig-
nificant mobilization of CFU-Cs to the peripheral blood.
Compared with AdNull or AdVEGF165, at day 14 after in-
jection, AdAng-1–mobilized CFU-Cs comprised predomi-
nantly CFU-M (*P , 0.005). The numbers of CFU-Cs re-
turned to control levels on day 28. The combination of
both AdVEGF165 and AdAng-1 enhanced the mobilization
of CFU-Cs (**P , 0.05).
The number of mobilized pluripotent hematopoietic cells
with stem cell potential, capable of forming spleen colonies
(CFU-S), was measured by injecting AdVEGF165 and/or
AdAng-1 or, as control, AdNull-mobilized PBMCs into
irradiated syngeneic mice (Fig. 2 B). Administration of
AdVEGF165 induced a 20-fold increase in peripheral blood
CFU-S by day 5 of treatment (Fig. 2 B). On the other hand,
administration of AdAng-1 induced a 2.5-fold increase in
peripheral blood CFU-S 14 d after injection. Coinjection of
both AdVEGF165 and AdAng-1 had a synergistic effect on
the number of mobilized CFU-S. Administration of AdNull
did not result in the mobilization of CFU-S.
The number of mobilized pluripotent hematopoietic
cells with BM-repopulating capacity was also determined
(Fig. 2 C) by allogeneic transplantation of VEGF165- and/
or Ang-1–mobilized PBMCs into lethally irradiated mice.
Injection of either AdVEGF165 and/or AdAng-1, but not
AdNull, resulted in mobilization of HSCs that were able to
engraft and rescue lethally irradiated mice. All mice trans-
planted with 106 PBMCs from AdNull-treated mice died
within 18 d (Fig. 2 D). However, 56% of the mice trans-
planted with PBMCs from AdVEGF and AdAng-1, 45% of
AdVEGF, and 22% of AdAng-1–treated mice survived be-
yond 150 d. These data suggest that overexpression of
VEGF165 and Ang-1 results in mobilization of pluripotent
hematopoietic cells with stem cell potential from BM to
the peripheral circulation.
Figure 1. AdVEGF165 and AdAng-1 pro-
mote mobilization of mature and immature
hematopoietic cells. Immunodeficient SCID
mice received AdVEGF165 (1.5 3 108 PFU)
and/or AdAng-1 (109 PFU), AdNull vector
(109 PFU), or the AdVEGF189 vector (2 3
108 PFU) by a single intravenous adminis-
tration on day 0. (A) Total WBCs were
counted using a Neubauer hematocytome-
ter and stained by crystal violet. n = 6. (B)
Morphological characterization of PBMCs
was determined by Wright-Giemsa staining.
Original magnification: 3200. (C) Differen-
tial leukocyte counts were obtained by ex-
amining the blood smears from each mouse
(200 cells counted/smear). n = 4.1009 Hattori et al.
AdVEGF165  and AdAng-1 Induce the Mobilization of
CEPs. We have shown that a subset of mobilized circu-
lating VEGFR21 PBMCs contain a unique population of
marrow-derived endothelial cells, namely CEPs (2, 4).
AdVEGF165 caused mobilization of CEPs to the peripheral
blood on days 2, 5, and 7, with a return to control levels by
day 14 (Fig. 3, A and B). Administration of AdVEGF165 and
AdAng-1 into SCID mice resulted in increased levels of
circulating VEGFR21CD11b2 cells, 7 d (15.3 6 2.5%)
and 14 d (11.1 6 4.1%) after the start of treatment (Fig. 3
B). Mobilized CEPs can be distinguished from mature en-
dothelial cells by their capacity to form late-outgrowth col-
onies (CFU-ECs) (20). In contrast to mature endothelial
cells, which form early outgrowth colonies, CEPs form
rapidly proliferating endothelial colonies 3–4 wk after initi-
ation of culture. Incubation of mobilized VEGFR21 PBMCs
with VEGF and FGF-2 (basic FGF) on collagen-coated
plastic dishes resulted in the generation of early and late
outgrowth DiI-Ac-LDL1 endothelial cells (CFU-ECs; Fig.
3, C and D). The majority of the colonies formed (Fig. 3,
E, F, and G) were composed of late outgrowth endothelial
cells, suggesting that VEGF and Ang-1 promote the mobi-
lization of BM-derived CEPs.
Prolonged Plasma Elevation of VEGF165 and Ang-1 Results
in Cellular and Vascular Remodeling of BM and Spleen. The
sustained chronic elevation of VEGF165 and Ang-1 within
1 wk resulted in the initial stimulation of hematopoiesis
with increased BM cellularity and proliferation of ery-
Figure 2. AdVEGF165 and/or AdAng-1 induce peripheral mobili-
zation of hematopoietic progenitor cells and stem cells. (A) The
number of mobilized progenitors was determined using standard
CFU assays. Large numbers of progenitors were mobilized by VEGF
(day 5, predominantly CFU-GM) and Ang-1 (day 14, predomi-
nantly CFU-M) (n = 4). The pluripotency of the mobilized cells was
determined by CFU-S assay (B) and BM repopulating assay (C and
D). Compared with AdVEGF, the combination of AdVEGF plus
AdAng-1 induced significant long-term mobilization of CFU-S up
to 21 d. Days 3, 7, and 14, *P , 0.01; day 21, **P , 0.05. Ang-1,
VEGF, or combined VEGF and Ang-1 promoted mobilization of
BM repopulating cells (n = 9). PBMCs (106 cells) from SCID mice
(H-2Kd) treated with AdNull, AdVEGF165, AdAng-1, or a combina-
tion (AdVEGF165 and AdAng-1) were transplanted into irradiated
C57BL/6 (H-2Kb) mice by intravenous injection on day 0. (C) The
number of engrafted H-2Kd cells was determined by flow cytometry.
Compared with the AdNull group, AdAng-1– and AdVEGF-treated
mice showed significant mobilization of cells capable of reconstitut-
ing hematopoiesis in lethally irradiated mice. **P , 0.05. In contrast,
all the mice transplanted with PBMCs from the peripheral blood of
AdNull-treated mice failed to engraft. (D) As a control group, 90%
of the mice transplanted with untreated BM (BMT group) were en-
grafted and survived the effects of lethal irradiation.1010 VEGF and Ang-1 Stimulate Postnatal Hematopoiesis
Figure 3. AdVEGF165 and Ang-1 promote mobilization of CEPs with late out-
growth potential. (A) Mobilized PBMCs were isolated from AdVEGF165- and/or
AdAng-1– or AdNull-treated SCID mice on days 0–28 and stained with FITC-con-
jugated anti-VEGFR2 (clone DC101) mAb and propidium iodide. (A) 104 cells were
analyzed on a Beckman Coulter Elite flow cytometer, and representative percentages
of positive populations in PBMCs are shown. (B) The percentages of mobilized cir-
culating VEGFR21CD11b2 cells from AdVEGF165- and/or AdAng-1– or AdNull-
treated SCID mice (n = 3) are shown from days 0 –28. For quantification of CEPs
with late outgrowth potential, mobilized PBMCs were obtained from AdVEGF165
and/or AdAng-1 or AdNull-treated SCID mice on days 0–21 and plated in the pres-
ence of endothelial growth medium (reference 13) on collagen/fibronectin-coated
plastic dishes. Endothelial colonies (CFU-ECs) were identified by vWF immu-
nostaining and metabolic labeling with DiI-Ac-LDL. (C) CFU-ECs proliferated 2 wk
after the start of culture (mean 6 SEM). Colonies that formed within the first 3 d
(early outgrowth) and colonies formed 14 d (late outgrowth) after vector administra-
tion were quantified by vWF and DiI-Ac-LDL labeling. (D) The majority of CFU-
EC proliferated 3 wk after the start of culture, forming focal DiI-Ac-LDL1 endothe-
lial monolayers as seen at 14 (E), 20 (F), and 25 d (G).1011 Hattori et al.
throid, myeloid, and megakaryocytic lineages compared with
BM of AdNull-treated SCID mice (Fig. 4, A and B).
However, by 2–3 wk there was a gradual decrease in BM
cellularity and remodeling of the BM architecture with
concomitant profound splenomegaly of AdVEGF- and
AdAng-1–treated SCID mice. Histological examination of
the BM at day 14 demonstrated progressive increase in si-
nusoidal space and proliferation of capillaries (Fig. 4 C). By
day 60, at a time when the plasma levels of VEGF and
Ang-1 returned to baseline, the overall BM cellularity and
vascularity returned to baseline levels (Fig. 4 D). These BM
architectural changes were much less pronounced when ei-
ther VEGF or Ang-1 was overexpressed.
Given that SCID mice have an abnormal splenic structure,
evaluation of the splenic cellular architecture after injection
with VEGF or Ang-1 is not feasible. Therefore, immuno-
competent BALB/c mice were injected subcutaneously with
100 ng of recombinant VEGF on a daily basis for 2 wk. After
Figure 4. Chronic elevation
of AdVEGF and AdAng-1 in-
duces vascular remodeling of
BM with concomitant spleno-
megaly. Administration of
AdVEGF165 and/or AdAng-1 or
AdNull was performed as de-
scribed in the legend to Fig. 1.
On days 7, 14, and 60 after inoc-
ulation three mice in each group
were killed, and their organs
were collected and processed for
histological analysis. Paraffin sec-
tions of the spleen and BM were
stained by hematoxylin and
eosin. Representative BM sec-
tions from day 7 after AdNull
(A) and day 7 after AdVEGF165
plus AdAng-1 (B) are shown.
BM cellularity was increased in
AdVEGF165  plus AdAng-1–
treated SCID mice at day 7 com-
pared with AdNull-treated mice.
(C) On day 14, sinusoidal space
and proliferation of capillaries
were progressively increased in
the BM of AdVEGF165 plus
AdAng-1–treated SCID mice.
(D) BM cellularity and vascular-
ity returned to baseline levels on
day 60. Macroscopic and micro-
scopic observations of spleens
from BALB/c mice treated with
recombinant VEGF (E and G) or
PBS as a control (F and H) on
day 10 are shown. These mice
were injected subcutaneously
with 100 ng of recombinant
VEGF or only vehicle, on a daily
basis. There was a remarkable in-
crease in the size of the spleen
and follicular hyperplasia 10 d af-
ter VEGF treatment compared
with control. Original magnifi-
cations: (A, C, D, G, and H)
3200; (B) 3400; (E and F) 320.1012 VEGF and Ang-1 Stimulate Postnatal Hematopoiesis
2 wk, at the time when there was a relative decrease in BM
cellularity (1.9 6 0.3 3 107/femur from VEGF-treated mice
compared with 2.5 6 0.1 3 107/femur for normal BALB/c
mice, P , 0.01), there was a remarkable increase in spleen
size (Fig. 4, E and F). Compared with the control group
(Fig. 4 H), there was increased cellularity and follicular hy-
perplasia in the spleen of VEGF-treated group (Fig. 4 G;
0.3 6 0.2 3 108 compared with 2.4 6 0.3 3 108 for normal
BALB/c mice, P , 0.005). Splenomegaly and follicular hy-
perplasia were reversed after cessation of treatment.
Mobilization of Leukocytes by AdVEGF165 Is Mediated
Primarily through VEGFR2 Signaling. Murine VEGFR2
(Flk-1), which is expressed on subsets of HSCs and CEPs,
mediates signals that may not only promote proliferation
but also stimulate chemotaxis of endothelial cells. There-
fore, we postulated that the primary mechanism whereby
VEGF induces mobilization of HSCs and CEPs is through
activation of VEGFR2. Injection of a neutralizing mAb to
murine VEGFR2 (clone DC101) 2 d after AdVEGF165 in-
jection significantly blocked VEGF165-induced mobiliza-
tion of leukocytes (Fig. 5, A and B) and CFU-Cs (Fig. 5 C)
to the peripheral circulation. However, DC101 failed to
inhibit Ang-1–induced migration of HSCs, suggesting that
Ang-1–delayed mobilization of HSCs and CEPs requires
Tie-2 signaling and is therefore independent of the
VEGFR2/VEGF signaling pathway.
Discussion
In this report, we have demonstrated that the elevation
of VEGF165 and/or Ang-1 plasma levels by Ad vectors re-
sults in robust mobilization of CEPs and hematopoietic
progenitors and HSCs (CFU-S, marrow repopulating cells)
to the peripheral circulation. Although VEGF165 alone
could also induce splenomegaly and increase BM cellular-
ity, the sustained elevation of both VEGF165 and Ang-1 was
essential to induce significant remodeling of BM vascular
architecture, with concomitant mobilization to the ex-
tramedullary organs, resulting in profound splenomegaly.
Elevation of Ang-1 alone did not affect the size of the
Figure 5. Neutralizing mAb to VEGFR2 inhibits mobilization of leukocytes and hematopoietic progenitor cells induced by AdVEGF165 but not
AdAng-1. (A) SCID mice were inoculated with AdVEGF165 (1.5 3 108 PFU) or AdNull (109 PFU) on day 0. Half of the AdVEGF165-treated mice re-
ceived 800 mg of anti-VEGFR2 (DC101) mAb at 2-d intervals starting from day 2. Total WBCs are expressed as the mean 6 SEM (n = 8). d,
AdVEGF165; m, AdVEGF165 1 DC101; j, AdNull. (B) SCID mice inoculated with AdVEGF165 (1.5 3 108 PFU) and AdAng-1 (109 PFU) received 800
mg of anti-VEGFR2 (DC101) at 2-d intervals starting from day 0. AdAng-1 (109 PFU) inoculated SCID mice were used as a control. Total WBCs were
quantified using a Neubauer hematocytometer. All data are expressed as the mean 6 SEM (n = 8). n, AdAng-1; d, AdVEGF165 1 AdAng-1 1 DC101;
j, AdVEGF165 1 AdAng-1; r, AdNull. (C) PBMCs from AdAng-1 alone, AdVEGF165 1 AdAng-1 (treated or untreated with DC101), or AdNull-
treated mice were seeded into the colony assays and four types of CFU (CFU-GM, BFU-E, CFU-M, and CFU-GEMM) were scored at 3, 5, 14, and 28 d
after the onset of treatment. All data are expressed as the mean 6 SEM (n = 4). Data points achieving statistical significance are shown. *P , 0.005.1013 Hattori et al.
spleen or cellularity of the BM, suggesting that combined
signaling through VEGFR2/VEGF and Ang1/Tie-2 sig-
naling pathways plays a key role in the regulation of organ-
specific hematopoietic activity.
The overexpression of VEGF165 induces a rapid (24–48 h)
mobilization of CEPs and HSCs, suggesting that the ef-
fect of VEGF165 is mediated through a chemokinetic pro-
cess. However, plasma elevation of Ang-1 requires at least
7 d to induce mobilization of CEPs and HSCs. The physi-
ological effect of VEGF is most likely not mediated
through BM endothelial cell leakiness since studies have
shown that Ang-1 prevents VEGF-induced vascular per-
meability (13, 18). In this regard, Ang-1 should have inhib-
ited the VEGF-induced mobilization of the HSCs and
CEPs. In contrast, Ang-1 promoted the mobilization of
HSCs and CEPs and synergized with VEGF in augmenting
its effect. Collectively, these data suggest that VEGF alone
or in combination with Ang-1 induce mobilization by di-
rectly interacting with stem cells or promoting remodeling
of the BM vasculature. It is conceivable that Ang-1 may al-
ter the adhesion molecule repertoire of BM endothelial
cells or HSCs, resulting in enhanced mobilization. Alterna-
tively, Ang-1 may sustain or promote the survival of Tie-21
HSCs and CEPs, inducing cell cycle shifts that may favor
their mobilization to the peripheral circulation.
VEGF has been shown to exert its pleiotropic effects on
endothelial cells through its receptors VEGFR1 and
VEGFR2. VEGFR2 has been shown to be the principal
mitogenic receptor for VEGF (21, 22), whereas VEGFR1
conveys signals for vascular remodeling. However,
VEGFR1 is expressed by various mature hematopoietic
cells, including dendritic and monocytic cells (23, 24),
whereas VEGFR2 is expressed by HSCs and CEPs (4).
Therefore, VEGF165-induced mobilization of mature cells
such as monocytes may be mediated though VEGFR1,
whereas mobilization of HSCs is most likely mediated
through VEGFR2 (6). Neutralizing mAb to VEGFR2 in-
hibited VEGF165-induced mobilization and splenomegaly,
suggesting that interaction of VEGF165 with VEGFR2 is
essential for mobilization and recruitment of HSCs. De-
layed mobilization in response to elevation in circulating
Ang-1 is most likely induced by interaction with either
Tie-21 on the stem cells (19) or because of remodeling of
the BM microenvironment.
Most in vivo experiments assessing the chemoattractant
properties of VEGF165 have been performed with injection
of recombinant VEGF165. However, given that the half-life
of VEGF165 in the circulation is only several minutes, it has
been difficult to evaluate the role of chronic VEGF165 re-
lease, as it may occur during tumor growth and metastasis
or myelodysplastic syndromes. Likewise, recombinant
Ang-1 is unstable and previous studies using Ang-1 protein
have failed to demonstrate a functional endpoint (21). It is
suggested that in contrast to VEGF165, whereby injection of
recombinant protein can induce mobilization of stem cells,
Ang-1 protein does not have enough biochemical stability
to exert any biological effect. Furthermore, given the de-
layed mobilization seen with Ang-1 treatment, injection of
AdAng-1 into SCID mice as opposed to immunocompe-
tent mice was the only means of sustaining the level of
Ang-1 long enough in vivo to observe its effects. There-
fore, the use of Ad vectors as regional delivery vehicles for
VEGF165 and Ang-1 provides ideal tools for studying the
role of these angiogenic factors in mobilization and recruit-
ment of HSCs and CEPs. In addition, given that VEGF189
is matrix bound, Ad vectors producing VEGF189 provide an
ideal mechanism to deliver this matrix-bound isoform of
VEGF regionally to the extramedullary hematopoietic mi-
croenvironments such as the liver.
We show that long-term overexpression of both
VEGF165 and Ang-1 is essential to induce an initial increase
in BM cellularity followed by remodeling of the BM archi-
tecture, with depletion of sinusoidal spaces of hematopoietic
cells and a parallel increase in BM vascularization and sple-
nomegaly. These results suggest that regional expression of
VEGF165 and Ang-1 in extramedullary organs may act syn-
ergistically to modulate postnatal hematopoiesis by inducing
extramedullary shifts in hematopoiesis or remodeling of vas-
cular architecture of sinusoidal BM endothelial cells. Re-
cently, it has been shown that plasma VEGF levels are sig-
nificantly elevated in myelodysplastic syndromes (17),
where the BM microenvironment is damaged by fibrotic
tissue. This raises the possibility that elevation of VEGF may
serve as one of the primary adaptive responses to compen-
sate for BM myelofibrosis, by promoting the relocalization
and recruitment of HSCs to other hematopoietic microen-
vironments such as the spleen, resulting in splenomegaly.
Mobilization of CEPs to the peripheral circulation may
play a critical role in regulating postnatal angiogenesis and
vasculogenesis. Based on the data presented here, high lev-
els of VEGF produced by tumors may result in the mobili-
zation of BM-derived CEPs to the peripheral circulation
and enhance their recruitment into the tumor vasculature.
Given that CEPs may also contribute to vascular healing,
overexpression of VEGF165 may promote the peripheral
blood mobilization and recruitment of CEPs to the injured
vascular bed, thereby accelerating wound healing.
As evidenced by the relative plasma levels of Ang-1 and
VEGF, higher levels of Ang-1 are necessary to induce mo-
bilization of HSCs and CEPs. Indeed, at doses .1.5 3 108
PFU of AdVEGF165, elevations of plasma VEGF were asso-
ciated with significant toxicity and resulted in the death of
the treated mice. Ang-1 does not exert any major physio-
logical effect at the lower doses (5 3 108 PFU); however,
when administered at higher doses (109 PFU) it had a po-
tent synergistic effect with VEGF in mobilizing HSCs and
CEPs. These differences in the dose response may be due
to the variable receptor densities or differential physiologi-
cal effects of the VEGF receptors and Tie-2. It is also con-
ceivable that expression of VEGFR2 (Flk-1) on HSCs and
CEPs is significantly higher than Tie-2.
These data set forth a novel paradigm for efficient mobi-
lization of HSCs and CEPs to the peripheral circulation.
This strategy facilitates recovery of large numbers of pluri-
potent HSCs and CEPs, which may be used for transplan-
tation or treatment of a wide variety of genetic and malig-1014 VEGF and Ang-1 Stimulate Postnatal Hematopoiesis
nant disorders. Whether transplantation of mobilized CEPs
in conjunction with mobilized HSCs will exert a synergis-
tic effect to enhance engraftment and reconstitution of he-
matopoiesis is the subject of future studies.
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